Is ICLR a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for ICON plc (ICLR) rests on Backlog and bookings momentum: ICON reported net bookings of about $2.9 billion and gross bookings of roughly $3.3 billion in Q1 2026, up around 22% year over year, with a net book-to-bill near 1.42. Revenue (TTM) is ~$8.1B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: ICON faces cyclical risk from pharmaceutical reprioritization, trial cancellations, and swings in biotech funding, all of which can slow bookings conversion. Whether ICLR is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
ICON plc (NASDAQ: ICLR) is a Dublin-headquartered contract research organization that provides outsourced clinical development services to pharmaceutical, biotechnology, medical device, and government clients. As of March 2026 it had roughly 40,350 employees across about 97 locations in 55 countries, and it manages studies spanning compound selection through Phase I to Phase IV trials. Revenue is booked against a large backlog, so bookings and book-to-bill ratios are watched as closely as reported sales. The investment picture in 2026 is a story of scale meeting a demand air pocket. First-quarter 2026 revenue was roughly $2.03 billion, up about 0.9% reported but down 1.9% at constant currency, while adjusted EPS fell to about $2.50 from $3.27 a year earlier as adjusted EBITDA margin dropped sharply. At the same time net bookings were about $2.9 billion with a book-to-bill near 1.42 and backlog around $22.7 billion, signaling that future work is being won even as current results soften. The stock trades at a low-teens trailing earnings multiple, reflecting caution about margins, a disclosed internal accounting investigation, and the pace of pharma spending recovery.
What's the case for buying ICLR?
1. Backlog and bookings momentum
ICON reported net bookings of about $2.9 billion and gross bookings of roughly $3.3 billion in Q1 2026, up around 22% year over year, with a net book-to-bill near 1.42. Backlog stood at approximately $22.7 billion, which provides multi-year revenue visibility if trials convert on schedule.
2. Structural CRO outsourcing growth
Large pharma and biotech continue to outsource more of clinical development to specialized providers. Industry estimates point to a global CRO market growing at a double-digit compound rate over the second half of the decade, which favors scaled full-service players like ICON that can run complex global trials.
3. Capacity and early-phase expansion
ICON has been investing in early-phase and first-in-human capabilities, including a new Clinical Research Unit in San Antonio and satellite outpatient clinics. Expanding early-phase capacity positions the company to capture work earlier in the drug-development funnel and deepen top-client relationships.
4. Valuation reset and cash generation
After a de-rating, ICON trades at a low-teens trailing earnings multiple with a forward multiple in the high single digits on 2026 guidance. If bookings translate into revenue and margins stabilize, the compressed valuation leaves room for re-rating, though that depends on demand recovery.
What are the risks to ICLR?
ICON faces cyclical risk from pharmaceutical reprioritization, trial cancellations, and swings in biotech funding, all of which can slow bookings conversion. Margin pressure has been acute, with adjusted EBITDA margin falling to about 15.6% in Q1 2026 from the high-teens to roughly 20% range previously. Concentration among a handful of Top 10 pharma clients means mergers or pipeline cuts at a few customers can materially affect revenue. The company disclosed an internal accounting investigation and potential restatements, which prompted at least one analyst downgrade and adds uncertainty until resolved. Full-year 2026 revenue guidance of roughly $7.85 billion to $8.15 billion sits below 2025 levels, reflecting both a divestiture and organic softness.
How is ICLR valued? (as of July 2026)
Snapshot for ICLR as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Market cap: ~$8.9B
- Revenue (TTM): ~$8.1B
- Q1 2026 revenue: ~$2.03B
- Q1 2026 adjusted EPS: ~$2.50
- P/E (trailing): ~14-15x
- 2026 revenue guidance: ~$7.85B-$8.15B
ICON reaffirmed full-year 2026 guidance of roughly $7.85 billion to $8.15 billion in revenue and about $10.00 to $11.00 in adjusted diluted EPS. The low-teens trailing multiple reflects softer near-term margins and demand, while backlog of around $22.7 billion underpins forward visibility. Figures are approximate and drawn from company filings and market data.
How do you decide if ICLR is a buy?
Rather than asking whether ICLR is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ICLR indirectly through an index or sector ETF before adding more.
For the full picture, see the ICLR stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ICLR against your real portfolio and see your actual exposure before deciding.
The bottom line on ICLR
The bottom line: ICON plc's story right now is Backlog and bookings momentum, with revenue (ttm) at ~$8.1B. If you believe that narrative continues, the call is about sizing ICLR sensibly and checking overlap with what you own; if you doubt it (the risk: iCON faces cyclical risk from pharmaceutical reprioritization, trial cancellations, and swings in biotech funding, all of which can slow bookings conversion.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ICLR with Walnut
Use ICON plc as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ICLR a good stock to buy right now?
+
The case for ICON plc right now is Backlog and bookings momentum, with revenue (ttm) at ~$8.1B. If you believe that thesis holds, ICLR is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is iCON faces cyclical risk from pharmaceutical reprioritization, trial cancellations, and swings in biotech funding, all of which can slow bookings conversion. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does ICON plc do?
+
ICON plc (NASDAQ: ICLR) is a Dublin-headquartered contract research organization that provides outsourced clinical development services to pharmaceutical, biotechnology, medical de
What are the main risks of ICLR?
+
ICON faces cyclical risk from pharmaceutical reprioritization, trial cancellations, and swings in biotech funding, all of which can slow bookings conversion. Margin pressure has been acute, with adjusted EBITDA margin falling to about 15.6% in Q1 2026 from the high-teens to roughly 20% range previously. Concentration among a handful of Top 10 pharma clients means mergers or pipeline cuts at a few customers can materially affect revenue. The company disclosed an internal accounting investigation and potential restatements, which prompted at least one analyst downgrade and adds uncertainty until resolved. Full-year 2026 revenue guidance of roughly $7.85 billion to $8.15 billion sits below 2025 levels, reflecting both a divestiture and organic softness.
What does ICON plc do?
+
ICON is a contract research organization that runs outsourced clinical trials and drug-development services for pharmaceutical, biotech, medical device, and government clients. It manages studies from early compound selection through Phase I to Phase IV, operating across dozens of countries.
Is ICLR a US stock?
+
ICON plc is headquartered in Dublin, Ireland, but its shares are listed on the NASDAQ under the ticker ICLR and trade in US dollars. It files periodic reports with the SEC as a foreign private issuer.
How big is ICON compared to competitors?
+
ICON is generally described as the world's second-largest CRO. IQVIA is larger, with roughly double the revenue and a much bigger market capitalization, while Medpace, Fortrea, and Charles River compete in overlapping segments.
Why did ICON's earnings fall in early 2026?
+
Q1 2026 adjusted EPS dropped to about $2.50 from $3.27 a year earlier, driven mainly by margin compression as adjusted EBITDA margin fell to roughly 15.6%. Revenue was about flat reported and slightly negative at constant currency amid softer demand.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ICLR; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.